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ABSTRACT 36 
Objective. While many studies have consistently found incomplete reporting of regression-37 
based prediction model studies, evidence is lacking for machine learning-based prediction 38 
model studies. We aim to systematically review the adherence of Machine Learning (ML)-39 
based prediction model studies to the Transparent Reporting of a multivariable prediction 40 
model for Individual Prognosis Or Diagnosis (TRIPOD) Statement.  41 
Study design and setting: We included articles reporting on development or external 42 
validation of a multivariable prediction model (either diagnostic or prognostic) developed 43 
using supervised ML for individualized predictions across all medical fields (PROSPERO, 44 
CRD42019161764).  We searched PubMed from 1 January 2018 to 31 December 2019. Data 45 
extraction was performed using the 22-item checklist for reporting of prediction model 46 
studies (www.TRIPOD-statement.org). We measured the overall adherence per article and per 47 
TRIPOD item.  48 
Results: Our search identified 24 814 articles, of which 152 articles were included: 94 (61.8%) 49 
prognostic and 58 (38.2%) diagnostic prediction model studies. Overall, articles adhered to a 50 
median of 38.7% (IQR 31.0-46.4) of TRIPOD items. No articles fully adhered to complete 51 
reporting of the abstract and very few reported the flow of participants (3.9%, 95% CI 1.8 to 52 
8.3), appropriate title (4.6%, 95% CI 2.2 to 9.2), blinding of predictors (4.6%, 95% CI 2.2 to 9.2), 53 
model specification (5.2%, 95% CI 2.4 to 10.8), and model’s predictive performance (5.9%, 54 
95% CI 3.1 to 10.9). There was often complete reporting of source of data (98.0%, 95% CI 94.4 55 
to 99.3) and interpretation of the results (94.7%, 95% CI 90.0 to 97.3).  56 
Conclusion. Similar to prediction model studies developed using conventional regression-57 
based techniques, the completeness of reporting is poor. Essential information to decide to 58 
use the model (i.e. model specification and its performance) is rarely reported. However, 59 
some items and sub-items of TRIPOD might be less suitable for ML-based prediction model 60 
studies and thus, TRIPOD requires extensions. Overall, there is an urgent need to improve the 61 
reporting quality and usability of research to avoid research waste.   62 
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What is new?  63 
• Key findings: Similar to prediction model studies developed using regression techniques, 64 
machine learning (ML)-based prediction model studies adhered poorly to the TRIPOD 65 
statement, the current standard reporting guideline.  66 
• What this adds to what is known? In addition to efforts to improve the completeness of 67 
reporting in ML-based prediction model studies, an extension of TRIPOD for these type of 68 
studies is needed.  69 
• What is the implication, what should change now? While TRIPOD-AI is under 70 
development, we urge authors to follow the recommendations of the TRIPOD statement 71 
to improve the completeness of reporting and reduce potential research waste of ML-72 
based prediction model studies.  73 
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INTRODUCTION 74 
Clinical prediction models are used extensively in healthcare to aid patient diagnosis and 75 
prognosis of disease and health status. A diagnostic model combines multiple predictors or 76 
test results to predict the presence or absence of a certain disorder, whereas a prognostic 77 
model estimates the probability of future occurrence of an outcome.1–3 Studies developing, 78 
validating, and updating prediction models are abundant in most clinical fields and their 79 
number will continue to increase as prediction models developed using artificial intelligence 80 
(AI) and machine learning (ML) are receiving substantial interest in the healthcare 81 
community.4  82 
ML, a subset of AI, offers a class of models that can iteratively learn from data, identify 83 
complex data patterns, automate model building, and predict outcomes based on what has 84 
been learned using computer-based algorithms.5,6 ML is often described as more efficient and 85 
accurate than conventional regression-based techniques. ML-based prediction models, 86 
correctly developed, validated, and implemented, can improve patient benefit, and reduce 87 
disease and health system burden. There is increasing concern of the methodological and 88 
reporting quality of studies developing prediction models, with research till date focusing on 89 
models developed with conventional statistical techniques such as logistic and Cox 90 
regression.7–11 Recent studies have found limited application of ML-based prediction models 91 
because of poor study design and reporting.12,13  92 
Incomplete (or unclear) reporting makes ML-based prediction models difficult to interpret 93 
and impedes validation by independent researchers, thus creating barriers to their use in 94 
daily clinical practice. Complete and accurate reporting of ML-based prediction model studies 95 
will improve its interpretability, reproducibility, risk of bias assessment, and applicability in 96 
daily medical practice and is, therefore, essential for high-quality research.14 To improve 97 
transparency and reporting of prediction model studies, the Transparent Reporting of a 98 
multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) Statement, a 99 
checklist of 22 items, was designed (www.tripod-statement.org).15,16 Specific guidance for ML-100 
based prediction model studies is currently lacking and has initiated the extension of TRIPOD 101 
for prediction models developed using ML or AI (TRIPOD-AI).17  102 
We conducted a systematic review to assess the completeness of reporting of ML-based 103 
diagnostic and prognostic prediction model studies in recent literature using the TRIPOD 104 
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Statement.15,16 Our results will highlight specific reporting areas that can inform reporting 105 
guidelines for ML, such as TRIPOD-AI. 17  106 
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METHODS  107 
Our systematic review protocol was registered (PROSPERO, CRD42019161764) and 108 
published.18 We reported this systematic review following the PRISMA statement.19 109 
 110 
Data source and search  111 
We searched PubMed on December 19, 2019 to identify primary articles describing 112 
prediction models (diagnostic or prognostic) using any supervised ML technique across all 113 
clinical domains published between 1 January 2018 and 31 December 2019. The search 114 
strategy is provided in the supplemental material.  115 
 116 
Study selection 117 
We included articles that described the development or validation of one or more 118 
multivariable prediction models using any supervised ML technique aiming for individualized 119 
prediction of risk or outcomes. As there is still no consensus on a definition of ML, we defined 120 
a ‘study using ML’ as a study that describes the use of a non-generalized linear models to 121 
develop or validate a prediction model (e.g. tree-based models, ensembles, deep learning). 122 
Hence, studies that claimed to have used ML, but they reported only regression-based 123 
statistical techniques were excluded from this systematic review (e.g. logistic regression, lasso 124 
regression, ridge regression and elastic net). Specifically, we focused on supervised ML, a 125 
subdomain of ML, that is characterized by using an algorithm that learns to predict from 126 
labelled outcome examples. Example are random forest, support vector machine, neural 127 
network, naïve bayes, and gradient boosting. 128 
Articles reporting on the incremental value or model extension were also included. We 129 
included all articles regardless of study design, data source, or patient-related health 130 
outcome. Articles that investigated a single predictor, test or biomarker, or its causality with 131 
an outcome were excluded. Articles using ML to enhance reading of images or signals, or 132 
articles where ML models only used genetic traits or molecular markers as predictors, were 133 
also excluded. We also excluded systematic reviews, conference abstracts, tutorials, and 134 
articles for which full-text was unavailable via our institution. We restricted the search to 135 
human subjects and English-language articles. Further details are stated in our protocol.18  136 
 137 
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Two researchers, from a group of seven (CLAN, TT, SWJN, PD, JM, RB, JAAD), independently 138 
screened titles and abstracts to identify potentially eligible studies. Full-text articles were then 139 
retrieved, and two independent researchers reviewed them for eligibility using Rayyan.20 One 140 
researcher (CLAN) screened all articles and six researchers (TT, SWJN, PD, JM, RB, JAAD) 141 
collectively screened the same articles. Disagreements between reviewers were resolved by a 142 
third researcher (JAAD).  143 
Data extraction 144 
The data extraction form was based on the TRIPOD adherence assessment form (www.tripod-145 
statement.org).21 This form contains several adherence statements (hereafter called sub-146 
items) per TRIPOD item. Some items and sub-items are applicable to all types of studies, 147 
while others are only applicable to model development only or external validation only (Table 148 
1). To judge reporting of the requested information, sub-items were formulated to be 149 
answered with ‘yes’, ‘no’, ‘not applicable’. We amended the published adherence form by 150 
omitting the ‘referenced’ option because we checked the information in the references, 151 
supplemental material or appendix. Sub-items related to items 10b and 16 were extracted 152 
per model, rather than at study-level, as they refer to model performance.  153 
 154 
We performed a double data extraction for included articles. Two reviewers independently 155 
extracted data from each article using the standardized form which was available in REDCap, 156 
a data capture tool.22 To accomplish consistent data extraction, the form was piloted by all 157 
reviewers on five articles. One researcher (CLAN) extracted data from all articles and six 158 
researchers (TT, SWJN, PD, JM, RB, JAAD) collectively extracted data from the same articles. 159 
Discrepancies in data extraction were discussed and resolved between each pair of reviewers.  160 
 161 
Data synthesis and analysis 162 
We categorized prediction model studies as prognosis or diagnosis and classified studies by 163 
research aim: development (with or without internal validation), development with external 164 
validation (same model), development with external validation (different model), and external 165 
validation only. Detailed definition of research aims can be found in the supplemental 166 
material. Where articles described the development and/or validation of more than one 167 
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prediction model, we chose the first ML model reported in the methods section for 168 
extraction.  169 
We scored each TRIPOD item as ‘reported’ and ‘not reported’ based on answers to 170 
corresponding sub-items.  If the answer to all sub-items of a TRIPOD item is scored ‘yes’ or 171 
‘not applicable’, the corresponding item was considered ‘reported’. Two analyses were 172 
conducted: adherence per item and overall adherence per article. We calculated the 173 
adherence per TRIPOD item by dividing the number of studies that adhered to a specific item 174 
by the number of studies in which the item was applicable. The total number of TRIPOD items 175 
varies by the type of prediction model study (Table 1). We calculated the overall adherence to 176 
TRIPOD per article by dividing the sum of reported TRIPOD items by the total number of 177 
applicable TRIPOD items for each study. If an item was ‘not applicable’ for a particular study, 178 
it was excluded when calculating the overall adherence, both in the numerator and 179 
denominator.21 Analyses were performed using R version 3.6.2 (R Core Team, Vienna, Austria). 180 
Results were summarized as percentages, medians, ranges, and using visual plots. 181 
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RESULTS 182 
We identified 24 814 unique articles, of which we sampled ten random sets of 249 articles 183 
each with sampling replacement for screening. We screened the title and abstracts of 2 482 184 
articles, screened full-text of 312 articles and included 152 eligible articles (Figure 1).   185 
 186 
We included 94 (61.8%) prognostic and 58 (38.2%) diagnostic prediction model studies. 132 187 
(86.8%) articles described development with internal validation and 19 (12.5%) development 188 
with external validation (same model). One (0.6%) article was development with external 189 
validation (different model) and was included as a development with internal validation study 190 
in the present analysis. Prediction models were developed most often in oncology (21/152 191 
[13.8%]). Detailed description of the included studies is provided in supplemental material.  192 
 193 
Across the 152 studies, 1429 models were developed and 219 were validated, with a range of 194 
1 to 156 for both types of studies. The most commonly used ML techniques for the first 195 
reported model were Classification and Regression Tree (CART [10.1%]), Support Vector 196 
Machine (SVM [9.4%]) and Random Forest (RF [9.4%]). Alongside ML techniques, 19.5% of 197 
studies reported the development of a model using conventional statistical techniques, such 198 
as logistic regression. Five out of 152 studies (3.3%, 95% CI 1.4% to 7.5%) stated following the 199 
recommendations of the TRIPOD Statement.  200 
 201 
Overall adherence per TRIPOD item  202 
Five TRIPOD items reached at least 75% adherence (background, objectives, source of data, 203 
limitations, and interpretation), whilst 12 TRIPOD items were below 25% adherence (Figure 2). 204 
Results for the overall adherence per TRIPOD item stratified by study type, diagnosis and 205 
prognosis, and publication year are shown in Table 2.  206 
 207 
Title and abstract (item 1 and 2) 208 
Seven out of 152 studies (4.6%, 95% CI 2.2 to 9.2) completely adhered to title 209 
recommendations. Description of type of prediction model study (sub-item 1.i) was poorly 210 
reported (11.2%, CI 7.0 to 17.2), but outcome to be predicted (sub-item 1.iv) was well 211 
reported (91.4%, CI 85.9 to 94.9). No study fully reported item 2, abstract (0.0%, CI 0.0%to 212 
2.5).  213 
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 214 
Introduction (item 3) 215 
Background and objectives were most often reported TRIPOD items. Background was 216 
provided in 123 studies (80.9%, 95% CI 73.9 to 86.4), and the objectives were reported in 124 217 
studies (81.6%, CI 74.6 to 86.9).  218 
 219 
Methods (item 4-12) 220 
Source of data was the most often reported item in the methods section, and across all 221 
TRIPOD items (98.0%, 95% CI 94.4 to 99.3). Study setting was reported in 107 studies (70.4%, 222 
CI 62.7 to 77.1), eligibility criteria in 105 (69.1%, CI 61.3 to 75.9), and handling of predictors in 223 
105 out of 152 studies (69.1%, CI 61.3 to 75.9). Ten studies assessed risk groups and five 224 
reported complete information (50.0%, CI 23.7 to 76.3). Differences between development 225 
and validation set were reported in 10 out of 19 applicable studies (52.6%, CI 31.7 to 72.7). 226 
For 72 studies, definition of outcome was reported (47.4%, CI 39.6% to 55.3). Key study dates 227 
such as start and end date of accrual, and length of follow-up were completely reported in 56 228 
studies (36.8%, CI 29.6 to 44.7). Details of treatment were reported in 36 out of applicable 116 229 
studies (31.0%, CI 23.3 to 39.9). Blinding of outcome and predictors were reported in 49 230 
(32.2%, CI 25.3 to 40.0) and 7 studies (4.6%, CI 2.2 to 9.2), respectively.  231 
 232 
Forty-four studies reported how missing data were handled (28.9%, 95% CI 22.3 to 36.6). The 233 
missing data item consists of four sub-items of which three were rarely addressed in included 234 
studies. Within 28 studies that reported handling of missing data: three studies reported the 235 
software used (10.7%, CI 3.7 to 27.2), four studies reported the variables included in the 236 
procedure (14.3%, CI 5.7 to 31.5) and no study reported the number of imputations (0.0%, CI 237 
0.0 to 39.0). Predictor definitions were given in 32 out of 152 studies (21.1%, CI 15.3 to 28.2), 238 
and justification of study size was reported in 27 studies (17.8%, CI 12.5 to 24.6). Model 239 
building procedures, such as predictor selection and internal validation, were reported in 22 240 
out of 152 studies (14.5%, CI 9.8 to 20.9). Internal validation, a sub-item of item 10b, was one 241 
of the most reported sub-items across studies (91.4%, CI 85.9 to 94.9).  242 
 243 
Reporting of measures used to assess and quantify the predictive performance was complete 244 
in 19 studies (12.5%, 95% CI 8.2 to 18.7). Though 106 studies (69.7%, CI 62.0 to 76.5) reported 245 
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discrimination (sub-item 10d.i), only 19 studies (12.5%, CI 8.2 to 18.7) reported calibration 246 
(sub-item 10d.ii). Definitions of discrimination and calibration are stated in supplemental 247 
material. Other performance measures (sub-item 10d.iii), for example sensitivity, specificity, or 248 
predictive values, were reported in 124 studies (81.6%, CI 74.7 to 86.9).  249 
 250 
Results (item 13-17) 251 
Study participant characteristics were reported in 38 out of 152 studies (25.0%, 95% CI 18.8 to 252 
32.4). Basic demographics, at least age and gender (sub-item 13b.i), were provided in 117 253 
studies (77.0%, CI 69.7 to 83.0), while summary information of the predictors (sub-item 13b.ii) 254 
was reported in 67 studies (44.1%, CI 36.4 to 52.0). Number of study participants with missing 255 
data for predictors (sub-item 13b.iii) was reported in 15 studies (24.2%, CI 15.2 to 36.2). 256 
Unadjusted associations were reported in 41 out of the 74 studies that reported regression-257 
based models alongside with ML-models (41.9%, CI 31.3 to 53.3). The number of participants 258 
and events were described in 37 studies (24.3%, CI 18.2 to 31.7).  In 31 out of 152 studies, an 259 
explanation on how to use the developed model to make predictions for new individuals was 260 
provided, often in the form of a scoring rule or online calculator (20.4%, CI 14.8 to 27.5). Flow 261 
of participants was reported in 6 studies (3.9%, CI 1.8 to 8.3) and model specification was 262 
reported in 6 out of 116 applicable studies (5.2%, CI 2.4 to 10.8). Model predictive 263 
performance was completely reported in 9 out of 152 studies (5.9%, CI 3.1 to 10.9).  264 
 265 
Discussion (items 18-20) 266 
Overall interpretation of results was reported in 124/152 studies (81.6%, 95% CI 74.7 to 86.9). 267 
Limitations of the study were reported in 144 studies (94.7%, CI 90.0 to 97.3). An 268 
interpretation of model performance in the validation set in comparison with the 269 
development set was given in 14/19 studies (73.7%, CI 51.2 to 88.2). Potential clinical use and 270 
implications for future research was reported in 61 studies (40.1%, CI 32.7 to 48.1).   271 
 272 
Other information (items 21 and 22)  273 
Availability of supplementary resources was mentioned in 93/152 studies (61.2, 95% CI 53.3 274 
to 68.6). Funding information was reported in 42 studies (27.6%, CI 21.1 to 35.2).  275 
 276 
Overall adherence per article 277 
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Overall adherence of studies to items of the TRIPOD Statement ranged between 13.0% and 278 
65.0%; median adherence was 38.7% (IQR 31.0 to 46.5). The completeness reporting in 279 
prognostic model studies was higher (median adherence=40.0% (IQR 33.3 to 46.8)) than 280 
diagnostic model studies (median adherence=35.7% (IQR 30.2 to 45.0)) (Figure 3). Moreover, 281 
median adherence was 40.6% (CI 28.6 to 46.1) in development (with internal validation) 282 
studies, compared to 37.9% (CI 31.0 to 46.4) in development with external validation studies.  283 
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DISCUSSION  284 
We conducted a systematic review of ML-based diagnostic and prognostic prediction model 285 
studies and assessed their adherence to the TRIPOD Statement. We found that ML-based 286 
prediction model studies adhere poorly to the TRIPOD Statement reporting items.  287 
 288 
Complete reporting in titles and abstracts is crucial to identify and screen articles. However, 289 
titles and abstracts were fully reported in less than 5% of articles. In addition, information 290 
about methods was infrequently reported. Complete and accurate reporting of the methods 291 
used to develop or validate a prediction model facilitates external validation, as well as 292 
replication of study results by independent researchers. For example, to enhance 293 
transparency and risk of bias assessment, it is recommended to report the number of 294 
participants with missing data and report how missing data were handled in the analysis. 295 
Handling of missing data was seldom reported, but this may be partially explained by the fact 296 
that some ML techniques can handle missing data by design (e.g. sparsity aware splitting in 297 
XGBoost and surrogate splits in decision trees).23,24 Also most studies divided a single dataset 298 
into three: training, validation and test set; the last is used for internal validation. The split 299 
sample approach for internal validation was among the most reported sub-items in our 300 
sample, but several methodological studies and guidelines have long discouraged this 301 
approach.25 We included diagnostic model studies that used images as one of the predictors, 302 
and deep learning. Often, these studies use several numerical variables based on pixels or 303 
voxels and build prediction models based on several layers of statistical interaction. Both 304 
topics are challenging to report due to number of variables used and poor interpretability of 305 
interactions. This may explain why diagnostic ML-based model studies were slightly worse 306 
reported compared to prognostic studies.  307 
 308 
Overall, most articles adhered to less than half of the applicable items considered essential 309 
for complete reporting. Authors may have avoided reporting specific details about methods 310 
and results because their objective may be to explore the data and modeling technique 311 
accuracy, rather than build models for individualized predictions in “real world” clinical 312 
settings.  However, high-quality reporting is also essential for reproducibility and replication. 313 
Also, most developed models were unavailable for replication, assessment, or clinical 314 
application. Only five studies reported using the TRIPOD Statement for reporting their 315 
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research. Although TRIPOD was published and disseminated in 2015, it is infrequently used 316 
for reporting of ML-based prediction model studies.  317 
 318 
Previous systematic reviews have shown poor reporting of regression-based prediction 319 
model studies. 7,8,10 One study assessed the completeness of reporting of articles published in 320 
high impact journals during 2014 within 37 different clinical fields. In 146 studies, over half of 321 
TRIPOD items were not fully reported, obtaining an overall adherence of 44% (IQR 35.0 to 322 
52.0). Comparable to our study, the review found poor reporting of the title, abstract, model 323 
building, model specification and model performance.7 A recent study assessed the 324 
completeness of reporting of deep learning-based diagnostic model studies. Although they 325 
developed their own data extraction for reporting quality, authors found poor reporting of 326 
demographics, distribution of disease severity, patient flow, and distribution of alternative 327 
diagnosis.26 These items were also inappropriately reported in our study with a median 328 
adherence between 0.0% and 47.3%. Another systematic review that assessed studies 329 
comparing the performance of diagnostic deep learning algorithms for medical imaging 330 
versus expert clinicians reported the overall adherence to TRIPOD was poor with a median of 331 
62.0% (45.0 to 69.0).27 In line with our results, a study about the performance of ML models 332 
showed that 68.0% of included articles had unclear reporting.12 333 
 334 
To our knowledge, this is the first systematic review evaluating the completeness of reporting 335 
of supervised ML-based prediction model studies in a broad sample of articles. We ran a 336 
validated search strategy and performed paired screening. We also used a contemporary 337 
sample of studies in our review (2018-2019). Though some eligible articles may have been 338 
missed, it is unlikely they would change the conclusions of this review.  339 
 340 
We used a systematic scoring-system enhancing the objectivity and consistency for the 341 
evaluation of adherence to a reporting guideline.21 We used the formal TRIPOD adherence 342 
form and checklist for data extraction and assessment; however, these were developed for 343 
studies developing prediction models with regression techniques. Although we applied the 344 
option ‘not applicable’ for items that were unrelated to ML and items were excluded when 345 
calculating overall adherence, our results should be interpreted within this context.  346 
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While some items and sub-items may be less relevant for prediction models developed with 347 
ML techniques, other items are more relevant for transparent reporting in these studies. For 348 
example, source of data (4a), study size (8), missing data (9), transformation of predictors 349 
(10a.i), internal validation (10b.iv), and availability of the model (15b) acquire new relevance 350 
within the context of ML-based prediction model studies. As ML techniques are prone to 351 
overfitting, we recommend to extend item 10b of the TRIPOD adherence form to include a 352 
new sub-item specifically related to penalization or shrinkage techniques. New reporting 353 
items such as the hardware (i.e. technical aspects) that was used to develop or validate an 354 
algorithm in images studies are needed, as well as data clustering. New practices such as 355 
explaining models through feature importance plot or tuning of hyper-parameters could be 356 
also added to the extension of TRIPOD for ML-based prediction models. Items such as 357 
testing of interaction terms (Item 10b-iv), unadjusted associations (14b), and regression 358 
coefficients (15a) require updating. Despite these recommendations, most TRIPOD items and 359 
sub-items are still applicable for both, regression and ML techniques and should be used to 360 
improve reporting quality.  361 
 362 
We identified nearly 25 000 articles with prediction and ML-related terms within 2 years, 363 
similar to previous systematic reviews about deep learning models.28,29 The literature has 364 
become saturated with ML-based studies; thus, their identification, reporting and assessment 365 
becomes even more relevant. If studies are presented without essential details to make 366 
predictions in new patients, subsequent researchers will develop a new model, rather than 367 
validating or updating an existing model. Reporting guidelines aim to increase the 368 
transparent evaluation, replication and translation of prediction models into clinical 369 
practice.30 Some reporting guidelines for ML clinical prediction models have been developed. 370 
31,32 However, these guidelines are limited and do not follow the EQUATOR recommendations 371 
for developing consensus-based reporting guidelines.33 The improvement in reporting after 372 
the introduction of a guideline has shown to be slow.30 Improving the completeness of 373 
reporting of ML-based studies might be even more challenging given the number of 374 
techniques and associated details that need to be reported. There are also practical issues, 375 
like terminology used, word limits, or journal requirements, that are acting as barriers to 376 
complete reporting. To overcome these barriers, the use of online repositories for data, script, 377 
and complete pipeline could help researchers share their models with enough details to 378 
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make predictions in new patients and to allow external validation of the model. Our results 379 
will provide input and support for the development of TRIPOD-AI, an initiative launched in 380 
2019.17 We call for a collaborative effort between algorithm developers, researchers, and 381 
journal editors to improve the adoption of good scientific practices related to reporting 382 
quality.  383 
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CONCLUSION 384 
ML-based prediction model studies currently do not adhere well to the TRIPOD reporting 385 
guideline. More than half of the TRIPOD items considered essential for transparent reporting 386 
were inadequately reported, especially regarding details of title, abstract, blinding, model 387 
building procedures, model specifications and model performance. Whilst ML brings new 388 
challenges to the development of tailored reporting guidelines, our study serves as a baseline 389 
measure to define future updates or extensions of TRIPOD tailored to ML modelling 390 
strategies.   391 
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Table 1. TRIPOD adherence reporting items 
 










1. Title D,V      
2. Abstract   D,V      
Introduction    
3. Background and 
objectives 
a. Context and rationale D,V      
b. Objectives D,V      
Methods    
4. Source of data 
a. Source of data D,V      
b. Key dates D,V      
5. Participants 
a. Study setting  D,V      
b. Eligibility criteria D,V      
c. Details of treatment D,V       
6. Outcome 
a. Outcome definition D,V      






a. Predictors definition D,V      





8. Sample size Arrival at study size D,V      
9. Missing Data Handling of missing data D,V      
10. Statistical analysis 





b. Specification of the model, all 
model building procedures, and 




c. For validation, description of 




d. Specification of all measures 





e. Description of model updating V     n.a.  
11. Risk groups 
Details of how risk groups were 
created 
D,V       
12. Development vs. 
validation 
For validation, description of 
differences between 




Results    
13. Participants 















14. Model development 
a. Number of participants and 




b. Unadjusted association 
between each candidate 
predictor and outcome 
D       
15. Model specification 
a. Presentation of full prediction 
model 
D       





16. Model performance 





17. Model updating Results from any model updating V     n.a. 
Discussion    
18. Limitations Limitations D,V      
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19. Interpretation 
a. For validation, interpretation of 





b. Overall interpretation of results D,V      
20. Implications 
Potential clinical use of the model 
and implications for future 
research 
D,V 
     
Other information        
21. Supplementary 
information 
Availability of supplementary 
resources 
D,V 
     
22. Funding 
Source of funding and role of 
funders 
D,V 
     
Total number of applicable items for TRIPOD adherence score  31 37 
(n.a) No included studies reported external validation only or model updating (Item 10c, 10e, and 17)  
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Table 2. Adherence to TRIPOD items 
 
TRIPOD Items 

















 n=152 [95% CI] n=133 [95% CI] n=19 [95% CI] n=94 [95% CI] n=58 [95% CI] n=65 [95% CI] n=87 [95% CI] 
Title (1) 
4.6 [2.2 to 9.2] 3.8 [1.6 to 8.5] 10.5 [2.9 to 31.4] 7.4 [3.7 to 14.6] 0.0 [0.0 to 6.2] 3.1 [0.8 to 10.5] 5.7 [2.5 to 12.8] 
Abstract (2) 
0.0 [0.0 to 2.5] 0.00 [0.0 to 2.8] 0.00 [0 to 16.8] 0.0 [0.0 to 3.9] 0.0 [0.0 to 6.2] 0.0 [0.0 to 5.6] 0.0 [0.0 to 4.2] 
Background (3a) 
80.9 [73.9 to 86.4] 79.7 [72.1 to 85.7] 89.5 [68.6 to 97.1] 83.0 [74.1 to 89.2] 77.6 [65.3 to 86.4] 84.6 [73.9 to 91.4] 78.2 [68.4 to 85.5] 
Objectives (3b) 
81.6 [74.7 to 86.9] 78.9 [71.3 to 85.0] 100 [83.2 to 100] 83.0 [74.1 to 89.2] 79.3 [67.2 to 87.7] 84.6 [73.9 to 91.4] 79.3 [69.6 to 86.5] 
Source of data (4a) 
98.0 [94.4 to 99.3] 98.5 [94.7 to 99.6] 94.7 [75.4 to 99.7] 98.9 [94.2 to 99.9] 96.6 [88.3 to 99.0] 98.5 [91.8 to 99.9] 97.7 [92.0 to 99.4] 
Key dates (4b) 
36.8 [29.6 to 44.7] 38.3 [30.5 to 46.8] 26.3 [11.8 to 48.8] 33.0 [24.3 to 43.0] 43.1 [31.2 to 55.9] 40.0 [29.0 to 52.1] 34.5 [25.3 to 44.9] 
Study settings (5a) 
70.4 [62.7 to 77.1] 72.2 [64.0 to 79.1] 57.9 [36.3 to 76.9] 73.4 [63.7 to 81.3] 65.5 [52.7 to 76.4] 75.4 [63.7 to 84.2] 66.7 [56.2 to 75.7] 
Eligibility criteria (5b) 
69.1 [61.3 to 75.9] 71.4 [63.2 to 78.4] 52.6 [31.7 to 72.7] 72.3 [62.6 to 80.4] 63.8 [50.9 to 74.9] 69.2 [57.2 to 79.1] 69.0 [58.6 to 77.7] 
Details of treatment* (5c) 
31.0 [23.3 to 39.9] 28.7 [20.8 to 38.2] 46.7 [24.8 to 69.9] 30. [22.0 to 41.0] 32.1 [17.9 to 50.7] 25.5 [15.5 to 38.9] 35.4 [24.9 to 47.5] 
Outcome (6a) 
47.4 [39.6 to 55.3] 47.4 [39.1 to 55.8] 47.4 [27.3 to 68.3] 52.1 [42.1 to 61.9] 39.7 [28.1 to 52.5] 47.7 [36.0 to 59.6] 47.1 [37.0 to 57.5] 
Blinding of outcome (6b) 
32.2 [25.3 to 40.0] 33.1 [25.7 to 41.5] 26.3 [11.8 to 48.8] 40.4 [31.1 to 50.5] 19.0 [10.9 to 30.9] 35.4 [24.9 to 47.5] 29.9 [21.3 to 40.2] 
Predictors (7a) 
21.1 [15.3 to 28.2] 22.6 [16.3 to 30.4] 10.5 [2.9 to 31.4] 18.1 [11.6 to 27.1] 25.9 [16.3 to 38.4] 18.5 [10.9 to 29.6] 23.0 [15.4 to 32.9] 
Blinding of predictors (7b) 
4.6 [2.2 to 9.2] 5.3 [2.6 to 10.5] 0.00 [0.0 to 16.8] 2.1 [0.6 to 7.4] 8.6 [3.7 to 18.6] 0.0 [0.0 to 5.6] 8.0 [4.0 to 15.7] 
Study size (8) 
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Missing data (9) 
28.9 [22.3 to 36.6] 30.8 [23.6 to 39.1] 15.8 [5.5 to 37.6] 29.8 [21.5 to 39.7] 27.6 [17.8 to 40.2] 30.8 [20.9 to 42.8] 27.6 [19.3 to 37.8] 
Handling of predictors (10a) 
69.1 [61.3 to 75.9] 72.2 [64.0 to 79.1] 47.4 [27.3 to 68.3] 66.0 [55.9 to 74.7] 74.1 [61.6 to 83.7] 69.2 [57.2 to 79.1] 69.0 [58.6 to 77.7] 
Model building (10b) 
14.5 [9.8 to 20.9] 12.8 [8.1 to 19.5] 26.3 [11.8 to 48.8] 13.8 [8.3 to 22.2] 15.5 [8.4 to 26.9] 18.5 [10.9 to 29.6] 11.5 [6.4 to 19.9] 
Predictor’s calculation (10c) 
 - - - - - - - 
Performance measures (10d) 
12.5 [8.2 to 18.7] 12.0 [7.5 to 18.6] 15.8 [5.5 to 37.6] 19.1 [12.5 to 28.3] 1.7 [0.1 to 9.1] 10.8 [5.3 to 20.6] 13.8 [8.1 to 22.6] 
Model updating (10e) 
- - - - - - - 
Risk groups* (11) 
50.0 [23.7 to 76.3] 50.0 [23.7 to 76.3] 0.0  28.6 [8.2 to 64.1] 100.0 [43.9 to 100] 50.0 [15.0 to 85.0] 50.0 [18.8 to 81.2] 
Development vs. validation (12) 
52.6 [31.7 to 72.7] NA 52.6 [31.7 to 72.7] 33.3 [13.8 to 60.9] 85.7 [48.7 to 99.3] 44.4 [18.9 to 73.3] 60.0 [31.3 to 83.2] 
Flow of participants (13a) 
3.9 [1.8 to 8.3] 4.5 [2.1 to 9.5] 0.0 [0.0 to 16.8] 2.1 [0.6 to 7.4] 6.9 [2.7 to 16.4] 3.1 [0.8 to 10.5] 4.6 [1.8 to 11.2] 
Demographics (13b) 
25.0 [18.8 to 32.4] 26.3 [19.6 to 34.4] 15.8 [5.5 to 37.6] 22.3 [15.1 to 31.8] 29.3 [19.2 to 42.0] 29.2 [19.6 to 41.2] 21.8 [14.5 to 31.6] 
Distribution (13c) 
0.0 [0.0 to 16.8] NA 0.0 [0.0 to 16.8] 0.0 [0.0 to 24.2] 0.0 [0.0 to 35.4] 0.0 [0.0 to 29.9] 0.0 [0 to 27.8] 
Model development (14a) 
24.3 [18.2 to 31.7] 24.8 [18.2 to 32.8] 21.1 [8.5 to 43.3] 19.1 [12.5 to 28.3] 32.8 [22.1 to 45.6] 26.2 [17.0 to 38.0] 23.0 [15.4 to 32.9] 
Unadjusted association* (14b) 
41.9 [31.3 to 53.3] 41.2 [30.3 to 53.0] 50.0 [18.8 to 81.2] 50.0 [35.8 to 64.2] 30.0 [16.7 to 47.9] 37.5 [22.9 to 54.7] 45.2 [31.2 to 60.1] 
Model specification (15a) 
5.2 [2.4 to 10.8] 4.0 [1.6 to 9.8] 12.5 [3.5 to 36.0] 5.6 [35.8 to 12.4] 4.5 [1.3 to 15.1] 4.0 [1.1 to 13.5] 6.1 [2.4 to 14.6] 
Presentation (15b) 
20.4 [14.8 to 27.5] 20.3 [14.3 to 27.9] 21.1 [8.5 to 43.3] 21.3 [14.2 to 30.6] 19.0 [10.9 to 30.9] 23.1 [14.5 to 34.6] 18.4 [11.6 to 27.8] 
Model performance (16) 
5.9 [3.1 to 10.9] 5.3 [2.6 to 10.5]  10.5 [2.9 to 31.4] 9.6 [5.1 to 17.2] 0.0 [0.0 to 6.2] 7.7 [3.3 to 16.8] 4.6 [1.8 to 11.2] 
Updating results (17) 
 -  - - - - -  - 
Limitations (18) 
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Interpretation validation (19a) 
73.7 [51.2 to 88.2] NA 73.7 [51.2 to 88.2] 75.0 [46.8 to 91.1] 71.4 [35.9 to 91.8] 77.8 [45.3 to 93.7] 70.0 [39.7 to 89.2] 
Interpretation (19b) 
94.7 [90.0 to 97.3] 94.0 [88.6 to 96.9] 100 [83.2 to 100] 95.7 [89.6 to 98.3] 93.1 [83.6 to 97.3] 93.8 [85.2 to 97.6] 95.4 [88.8 to 98.2] 
Implications (20) 
40.1 [32.7 to 48.1] 39.1 [31.2 to 47.6] 47.4 [27.3 to 68.3] 41.5 [32.1 to 51.6] 37.9 [26.6 to 50.8] 43.1 [31.8 to 55.2] 37.9 [28.5 to 48.4] 
Supplemental Information (21) 
61.2 [53.3 to 68.6] 58.6 [50.1 to 66.7] 78.9 [56.7 to 91.5] 63.8 [53.8 to 72.8] 56.9 [44.1 to 68.8] 61.5 [49.4 to 72.4] 60.9 [50.4 to 40.2] 
Funding (22) 
27.6 [21.1 to 35.2] 26.3 [19.6 to 34.4] 36.8 [19.1 to 59.0] 28.7 [20.6 to 38.6] 25.9 [16.3 to 38.4] 24.6 [15.8 to 36.3] 29.9 [21.3 to 40.2] 
Item 10c, 10e and 17, could not be assessed as they are only applicable to studies reporting on external validation only and studies including model 
update which were unavailable in our sample; (*) If applicable to studies; (NA) Item not applicable to study type; red cells are items with reporting 
quality below 25%; green cells are items with reporting quality above 75%. CI: Confidence Interval.  
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